Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
04:05pm, Wednesday, 28'th May 2025
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
03:31pm, Wednesday, 14'th May 2025
Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highes
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
07:30am, Friday, 09'th May 2025
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation
07:30am, Wednesday, 07'th May 2025
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript
10:55pm, Tuesday, 06'th May 2025
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executiv
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
08:00pm, Tuesday, 06'th May 2025
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
06:30pm, Tuesday, 06'th May 2025
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to break-even earnings per share a year ago.
Supernus Announces First Quarter 2025 Financial Results
04:08pm, Tuesday, 06'th May 2025
First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the
Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - SUPN
07:30am, Tuesday, 06'th May 2025
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
07:20am, Monday, 05'th May 2025
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN
07:30am, Thursday, 01'st May 2025
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S
Supernus Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SUPN
07:30am, Wednesday, 30'th Apr 2025
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDA
SUPN ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Supernus Pharmaceuticals, Inc. Shareholders Who Lost Money
07:30am, Tuesday, 29'th Apr 2025
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDA
